RALPMH: Remote assessment of lung disease and impact on physical and mental health

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
09/03/2021		[X] Protocol		
Registration date 10/03/2021	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited 16/05/2024	Condition category Respiratory	[] Individual participant data		
10/03/2024	respiratory			

Plain English summary of protocol

Background and study aims

Chronic obstructive pulmonary disease (COPD) is the name for a group of lung conditions that cause breathing difficulties. The term ILD encompasses a wide range of conditions affecting the lung tissue (as opposed to asthma and COPD which affect the airways)

The study aims to investigate the potential benefit and feasibility of remote monitoring of patients' symptoms and physiology via wearables and phone sensors in patients with a range of high-burden pulmonary disorders.

Remote monitoring will use our open-source RADAR-base (https://radar-base.org) mHealth platform to collect and analyse multiple datasets associated with respiratory disorders. This will include continuous data collected from wearable devices (e.g. heart rate, spO2), including pulse oximeters, spirometer, mobile phones (audio, location), digital tests and smartphone symptoms questionnaires in 3 different disorder areas (COPD, ILD and Post Hospitalisation Covid). During these unprecedented times, an urgent measure must be taken to ensure vulnerable patients with diseases, like COPD and ILD, continue to receive the quality of care they need. Currently, COVID-19 is a challenge for anyone, but especially for such vulnerable patients with pre-existing conditions and diseases when their routine care cannot be done properly. Remote monitoring of physiology and symptoms of patients via wearable devices is more timely and essential than ever. It could be used to support these patients and detect any potential disease exacerbation or progression.

Who can participate?

Patients with Chronic Obstructive Pulmonary Disorder (COPD), Interstitial Lung Disease (ILD) and Post Hospitalised COVID-19 patients.

What does the study involve?

We use various devices to remotely collect data on your physiology like Heart Rate and Oxygen Saturation. You would also provide daily samples of Spirometry and Pulse Oximetry. A number of questionnaires are also delivered so we can collect information such as symptom reporting from you.

Wearing a Garmin Vivoactive 4 wristband, Using the https://radar-base.org platform Questionnaire App (aRMT), a smart Spirometer (NextFlow AirNext), and a Finger Pulse Oximeter.

What are the possible benefits and risks of participating?

This is a research study and does not have any clinical intervention or any benefit to your treatment. You may keep the pulse oximeter at the end of the study. All devices used conform to CE marked safety standards and should present no risk to you.

Where is the study run from?

The study is run out of the Royal Free Hospital and University College London. This is in collaboration with King's College London and The South London and Maudsley NHS Trust (UK).

When is the study starting and how long is it expected to run for? October 2020 to March 2023

Who is funding the study? National Institute for Health Research (NIHR) (UK).

Who is the main contact?

Dr Amos Folarin, amos.folarin@kcl.ac.uk

Contact information

Type(s)

Scientific

Contact name

Dr Amos Folarin

ORCID ID

https://orcid.org/0000-0002-0333-1927

Contact details

NIHR Maudsley Biomedical Research Centre
Department of Biostatistics & Health Informatics
SGDP Centre, IoPPN, Box PO 80
De Crespigny Park, Denmark Hill
London
United Kingdom
SE5 8AF
+44(0)2078480924
amos.folarin@kcl.ac.uk

Type(s)

Scientific

Contact name

Prof Joanna Porter

Contact details

University College Hospital 235 Euston Road London United Kingdom NW1 2BU +44(0)20 3447 9004 joanna.porter@ucl.ac.uk

Type(s)

Scientific

Contact name

Prof John Hurst

Contact details

Address Royal Free Hospital - UCL Respiratory Rowland Hill Street London United Kingdom NW3 2PF +44 (0) 207 472 6260 j.hurst@ucl.ac.uk

Type(s)

Scientific

Contact name

Mr Yatharth Ranjan

Contact details

Department of Biostatistics & Health Informatics SGDP Centre, IoPPN King's College London Box PO 80 De Crespigny Park, Denmark Hill London United Kingdom SE5 8AF +44(0)2078480924 yatharth.ranjan@kcl.ac.uk

Type(s)

Scientific

Contact name

Prof Richard Dobson

ORCID ID

https://orcid.org/0000-0003-4224-9245

Contact details

Department of Biostatistics & Health Informatics SGDP Centre, IoPPN King's College London Box PO 80 De Crespigny Park, Denmark Hill London United Kingdom SE5 8AF +44(0) 20 7848 0473 richard.j.dobson@kcl.ac.uk

Type(s)

Scientific

Contact name

Dr Joseph Jacob

Contact details

Centre for Medical Image Computing 1st Floor, 90 High Holborn London United Kingdom WC1V 6LJ +44(0)7511033666 j.jacob@ucl.ac.uk

Type(s)

Scientific

Contact name

Dr Malik Althobiani

Contact details

UCL Respiratory, Royal Free Campus 1st Floor – Room 1/647 Rowland Hill Street London United Kingdom NW3 2XP +447900002806 malik.althobiani.20@ucl.ac.uk

Type(s)

Scientific

Contact name

Dr Michele Orini

Contact details

9 Prescot Street, 1st Floor Aldgate London United Kingdom E1 8PR +44(0)7845067446 m.orini@ucl.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

274070

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

IRAS 274070

Study information

Scientific Title

Remote Assessment of Lung Disease and Impact on Physical and Mental Health

Acronym

RALPMH

Study objectives

Feasibility study for the use of wearable sensors (Garmin Vivoactive 4), spirometry (NuvoAir Airnext) and finger pulse oximetry for the purpose of remote and near real-time participant exacerbation and disease trajectory observation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 06/05/2021, West Midlands - Black Country Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS; +44 (0)207 104 8284; blackcountry.rec@hra.nhs.uk), ref: 21/WM/0087

Study design

Observational longitudinal

Primary study design

Observational

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Lung diseases (COPD, ILD, COVID19)

Interventions

This study will investigate the potential benefit and feasibility of multiparametric remote monitoring of patient symptoms and physiology using commercially available wearables sensors for heart rate, activity, SpO2; spirometry, phone sensors, questionnaires and digital tests in patients with a range of pulmonary disorders.

Participants with lung diseases are enrolled and will wear wearable devices, use spirometers, finger pulse oximeters and app delivered questionnaires to monitor their disease remotely and in real-time over the course of 6 months.

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Garmin Vivoactive 4, NuvoAir Airnext, and finger pulse oximetry

Primary outcome(s)

- 1. Participant acceptability (TAMF, Interview) and drop-out rates at end of the study. The study will test the feasibility of tasks for participants. On completion of data collection periods a measurement of total available data as a function of a theoretical maximum and data quality measured by a range of criteria including missingness and contiguity
- 2. Detection of clinically important events such as exacerbations (inc. sub-clinical exacerbation) and disease progression, ERS, Sensor data, near real-time, 6 months. Detect exacerbation /symptom e.g. changes in wearable data (e.g. HR, SpO2, Activity) before, during and after the reported period of exacerbation (symptoms, FVC, death). A real-time algorithm will be included to predict exacerbations with patients notified with the Exacerbation Rating Scale (ERS) to confirm the prediction at or close to the time of the event
- 3. Quantification of symptoms (physical and mental health), various symptom questionnaires and scales, 6 months
- 4. Impact of disease on mood and wellbeing/QoL, GAD/PHQ8, weekly for 6 months
- 5. The trajectory-tracking of main outcome variables, symptom fluctuations, sub-clinical exacerbations and ordering
- 6. Report longitudinal mental health symptoms measures as reported by GAD7 and PHQ8 associated with the three diseases
- 7. Fatigue is the major reported symptom for those experiencing "long COVID". A range of modalities for evaluating fatigue are included 1) Garmin Body Battery value and 2) Fatigue Severity Scale (FSS), continuous/weekly respectively, duration of study
- 8. The assessment of novel phone based tests (Audio, Breathing Tests see: non-questionnaire Active App tests) for remote monitoring of respiratory health. The ubiquity of smartphones presents an opportunity to use the phone itself as a health measuring tool for both application in COVID-19 as part of this study but also wider application to other respiratory diseases. These phone based tests will be compared with other devices such as Pulse, Heart Rate and Spirometry data to establish potential value

Key secondary outcome(s))

Measured at the end of the study using patient records and data recorded through wearable devices:

- 1. Proportion of participants that complete the study
- 2. Number of participants that experience one exacerbation within the stopping criteria for each group
- 3. Number of exacerbations that were detected by i) spirometry ii) PROMs iii) wearable data, within the stopping criteria for each group

Completion date

31/03/2023

Eligibility

Key inclusion criteria

COPD cohort

1. Clinical Conditions: 20 patients with a diagnosis of COPD

2. Gender: M/F

3. Age range: 18+ years

4. Prior mobile phone use: required

5: Willingness to use monitoring devices and complete study questionnaires

6. History of exacerbation: 2 or more exacerbations in last 1 yr

ILD cohort

1. Clinical Conditions: 20 patients with a diagnosis of interstitial lung disease

2. Gender: M/F

3. Age range: 18-90

4. Prior mobile phone use: required

5: Willingness to use monitoring devices and complete study questionnaires

COVID-19 cohort

1. Clinical Conditions: a clinical diagnosis of COVID-19 (within 4-13 weeks of enrolment) who either and report symptoms interfering with day to day activity present for more than 28 days following the onset of COVID-19

2. Gender: M/F

3. Age range: 18+

4. Prior mobile phone use: required

5: Willingness to use monitoring devices and complete study questionnaires

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

60

Key exclusion criteria

Non-English language Speaker

Date of first enrolment

24/05/2021

Date of final enrolment

30/06/2022

Locations

Countries of recruitment

United Kingdom

England

Study participating centre Royal Free Hospital

UCL Respiratory Rowland Hill Street London United Kingdom NW3 2PF

Study participating centre University College London Hospital

235 Euston Road London United Kingdom NW1 2BU

Sponsor information

Organisation

South London and Maudsley NHS Foundation Trust

ROR

https://ror.org/015803449

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

South London and Maudsley NHS Foundation Trust

Alternative Name(s)

Funding Body Type

Government organisation

Funding Body Subtype

Local government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Amos Folarin (amosfolarin@gmail.com). Data collected using the RADARbase platform (https://radar-base.org) flat files (.csv or .avro) from mobile phone sensor data (RADAR-base passive app), Garmin Vivosmart 4, NuvoAir AirNext Spirometer, Questionnaires collected with RADAR-base active app, Demographics data collected with REDCap. Strongly deidentified data are available on request on a collaborative basis (see comments on data anonymisation). Data may be stored for up to 15 years. On the basis of collaborative work. Signed "data access request" ("DAR") will also be needed. The researchers are open to considering most analyses provided they meet ethics requirements and anonymisation is preserved. The mechanism of data sharing is to be decided but it will probably be accessed on /via KCL infrastructure. Only the pseudonymised dataset is available for researchers. The pseudonymised dataset will be generated using mobile applications, wearable devices and sensors. These data will be collected using the novel mHealth platform RADAR Base (https://radar-base.org/) deployed on KCL servers. Data will be stored on a secure storage server administered by King's College London University (https://rosalind.kcl.ac.uk/) and KCL sFTP located in the KCL Institute of Psychiatry, Psychology & Neuroscience (IOPPN). The data will be analysed by the researchers with the help of clinicians involved in the study at UCL and KCL. Consent was obtained. Most data in the study are pseudonymised. Some data are considered potentially sensitive and are not shareable on this basis in a raw form (e.g. active speech test data). The researchers are bound by the ethics provided in the study

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		24/11/2023	14/05/2024	Yes	No
Results article		08/04/2024	16/05/2024	Yes	No
Protocol article		11/06/2021	29/07/2021	Yes	No
HRA research summary			28/06/2023		No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes